Singapore to Get First Claim to Any Successful Arcturus Vaccine

Aug. 4, 2020, 9:00 PM

Singapore sought out U.S. Covid-19 vaccine developer Arcturus Therapeutics Holdings Inc. and is funding its research in order to secure the first doses of any successful final product, in a reflection of the growing urgency in the race for immunization.

San Diego-based Arcturus, in a partnership with Duke-NUS Medical School, is now in the early stages of human testing with the goal of producing a single-shot vaccine to immunize the Southeast Asian country’s population, said Chief Executive Officer Joseph Payne.

“The understanding is that because Singapore funded and helped us develop the vaccine, our intention is to definitely play ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.